EPHA2 and ovarian carcinoma: A lack of prospective stratification by target expression, such as FOLR1, EphA2 and CD44, along with integration of companion imaging or biopsies being limited, leads to ‘nanotargets’ being rarely used to select patients for specific nanomedicine treatments; this signifies a central limitation and represents an area of improvement in upcoming ovarian cancer nanomedicine trials.